Latest Content

Brian Myre, MD, discusses phase 1 data with the novel in situ SYNC-T Therapy SV-102 and the ongoing phase 2 LEGION-100 study in prostate cancer.

Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.

The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.

Experts convened to discuss ADC sequencing strategies, biomarker testing infrastructure, and emerging data across cervical, ovarian, and endometrial cancers.

Frontline zanubrutinib plus rituximab yielded significant efficacy improvements over SOC chemoimmunotherapy for mantle cell lymphoma.

Mayo Clinic shows thymus preps CD8 T cells and uncovers molecular structures of PKCβ, a protein linked to cancer, refining immunotherapy.

In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.

Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.

Epcoritamab plus lenalidomide reduced the risk of disease progression or death vs R-GemOx in relapsed/refractory DLBCL in the EPCORE DLBCL-4 trial.

Romiplostim N01 supported platelet engraftment after unrelated umbilical cord blood transplantation with no serious TRAEs in hematologic malignancies.

The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.

A Dana-Farber team developed an artificial intelligence method that designs proteins to recognize and hold specific drug molecules.

SB27, a proposed pembrolizumab biosimilar, met primary end points in both a phase 1 pharmacokinetic and a phase 3 efficacy study.

Milana V. Dolezal, MD, MSci, notes how the CLEOPATRA trial paved the way for further breast cancer research and highlighted data from DESTINY-Breast09.

The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.

The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.

The enzalutamide bioequivalent received tentative FDA approval, pending patent expiry on branded Xtandi before final marketing authorization.

IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.

Real-world treatment with pegylated interferon alfa-2a tolerable, and treatment-related AEs were manageable in patients with cutaneous T-cell lymphoma.

The FDA approved a prefilled pen for the administration of ropeginterferon alfa-2b-njft in adult patients with polycythemia vera.

Translational profiling tied CCR4 loss, IL enrichment, and BCL-2 upregulation to mogamulizumab resistance; venetoclax may be a combination partner.

In a phase 1 trial, duvelisib plus nivolumab produced a 26% overall response rate in relapsed/refractory cutaneous T-cell lymphoma but was limited by immune-mediated toxicities.

Real-world mogamulizumab reduced skin symptoms and improved health-related quality of life in patients with mycosis fungoides and Sézary syndrome.

CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.

CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.

Dibotatug was deemed tolerable and produced robust responses across subgroups of patients with relapsed/refractory cytotoxic T/NK cell lymphomas.

BI-1808 as a single agent and in combination with pembrolizumab elicited responses and was generally well tolerated in patients with CTCL.

The final analysis of the Italian FIL-MOGA study showed an objective response lasting at least 4 months in 47% of patients and identified the measure as a surrogate for survival outcomes.

The CHMP has recommended datopotamab deruxtecan for patients with first-line metastatic TNBC who are not candidates for immunotherapy.

Roswell Park Comprehensive Cancer Center announces the release of an operative surgical manual for surgeons performing bladder cancer surgeries.

The resubmission of the BLA for RP1 has been accepted for review by the FDA for use in combination with nivolumab in advanced melanoma.

R. Lor Randall, MD, FACS, reviews a longitudinal study in osteosarcoma showing a strong correlation between ctDNA status and clinical outcomes like EFS.

In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.

Topical tofacitinib is tolerable and has shown preliminary efficacy in patients with early-stage mycosis fungoides.

Distinct somatic mutation profiles separated responders from non-responders to mogamulizumab in mycosis fungoides and Sézary syndrome.

Vernon Sondak, MD, discusses CSCC risk classification, adjuvant cemiplimab in extremely high-risk disease, and the promise of neoadjuvant immunotherapy.

Shane Lloyd, MD, MHS, and Christos Vaklavas, MD, were selected as new Huntsman Cancer Institute Translational Scholars for their leadership in bridging laboratory discoveries with clinical innovation.

Hagop Kantarjian, MD, discusses the arsenal of TKIs approved for chronic myeloid leukemia and how to navigate them regarding treatment selection.

Daratumumab-based retreatment remained active in a broadly inclusive, transplant-ineligible newly diagnosed multiple myeloma population.

Experts convened during an OncLive Scientific Interchange and Workshop to discuss evolving biomarker utilization and sequencing strategies in uveal melanoma.

The FDA has approved sacituzumab govitecan monotherapy and in combination with pembrolizumab in frontline TNBC.

Izalontamab brengitecan was approved in China for recurrent/metastatic NPC following disease progression on chemotherapy and PD-1/PD-L1 inhibition.

The FDA has approved palbociclib plus trastuzumab, with/without pertuzumab, and ET as maintenance in HR+, HER2+ metastatic breast cancer.